Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Entocort versus mesalazine in active Crohn's disease in Japan
2014-004132-20Phase 3
- Sponsor
- AstraZeneca
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Entocort with mesalazine (2 arms). Primary endpoint: Remission after 8 weeks.
02
Drugs
budesonideSalcrozine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-004132-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004132-20.